Recent Comments

Comment RSS

Erectile Dysfunction News and Research RSS Feed - Erectile Dysfunction News and Research

Erectile Dysfunction (ED) is defined as the consistent inability to attain and maintain an erection sufficient for satisfactory sexual intercourse. ED affects up to 30 million men in the United States, with 52% of men between the ages of 40 and 70 reporting difficulty with erectile function. By the year 2025, it is estimated that 322 million men worldwide will suffer from some degree of sexual dysfunction.

Pfizer’s Revatio Injection receives FDA approval

20. November 2009 09:18
Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations. [More]

Data from second positive pivotal study of PSD502 for treatment of PE presented

20. November 2009 00:52
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora")., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). [More]

Positive results from Sciele Pharma's second pivotal study of PSD502 for the treatment of PE

19. November 2009 08:36
At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). [More]

Sildenafil drug improves cardiac performance in young adults with congenital heart disease

19. November 2009 01:19
Heart function significantly improved in children and young adults with single-ventricle congenital heart disease who have had the Fontan operation following treatment with sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, say researchers from The Children's Hospital of Philadelphia. [More]

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

19. November 2009 00:44
Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED). [More]

Positive results from REVIVE, a phase 3 pivotal study of avanafil announced

18. November 2009 07:16
VIVUS, Inc. today announced positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED), in 646 patients. [More]

Sildenafil improves heart function in youngsters with single ventricle congenital heart disease

18. November 2009 02:49
Heart function significantly improved in children and young adults with single ventricle congenital heart disease who have had the Fontan operation following treatment with sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, say researchers from The Children's Hospital of Philadelphia. [More]

IntelGenx completes first successful human study of an anti-migraine film

17. November 2009 06:48
IntelGenx Corp. is pleased to announce the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The product (INT008) has been developed using IntelGenx's proprietary immediate release film "VersaFilm" drug delivery technology. VersaFilm provides a patent-protected method of formulating in a convenient and discrete dosage form. [More]

Posted in: Device / Technology News

Tags: , , ,

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

17. November 2009 03:13
BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for female sexual health, including LibiGel® for the treatment of hypoactive sexual desire disorder (HSDD), applauds the efforts of Boehringer Ingelheim to develop a therapy to treat this unmet medical need. [More]

Antidepressant drug is effective in treating women with low libido

17. November 2009 01:49
The drug flibanserin, which was originally created as an antidepressant, is effective in treating women with low libido, pooled results from three separate clinical trials have found. [More]

Posted in: Women's Health News | Pharmaceutical News

Tags: , , , ,

First human study to measure effects of BPA on male reproductive system

11. November 2009 03:18
High levels of workplace exposure to Bisphenol-A may increase the risk of reduced sexual function in men, according to a Kaiser Permanente study appearing in the journal Human Reproduction, published by Oxford Journals. [More]

Posted in: Men's Health News

Tags: , , , , , , ,

Can American ginseng relieve health problems?

5. November 2009 03:15
With the current outbreak of influenza-like illnesses, many people are trying to boost their immune systems with supplements. Ginseng is often a key ingredient, but its therapeutic use may extend far beyond that. Researchers are now investigating whether ginseng can help relieve health problems ranging from diabetes to depression to erectile dysfunction. [More]

Warner Chilcott initiates phase III trial of erectile dysfunction drug udenafil

4. November 2009 23:47
Dong-A PharmTech Co. Ltd., announced that its U.S. partner, Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED). Each randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of udenafil, an orally administered selective inhibitor of phosphodiesterase versus placebo. [More]

Scientists develop technique to predict new target diseases for existing drugs

4. November 2009 04:18
Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs. [More]

FDA-approved drug PEG-ADA shows positive results in relieving major complication of priapism

31. October 2009 00:49
Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.